Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7598488 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1LMNATSHRALOX5 | |
| SCHEMBL7598492 | 0.84 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1LMNATSHRALOX5 | |
| SCHEMBL251631 | 0.84 | ACHE (0.53) | SMN1; SMN2DRD2 | |
| SCHEMBL9387794 | 0.82 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1LMNATSHRALOX5 | |
| SCHEMBL7591567 | 0.81 | SIGMAR1 (0.44) | NOD2NOD1 | |
| SCHEMBL7591571 | 0.81 | SIGMAR1 (0.44) | NOD2NOD1 | |
| SCHEMBL7865669 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1LMNATSHRPOLB | |
| SCHEMBL7594215 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1LMNATSHRPOLB | |
| SCHEMBL7594219 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1LMNATSHRPOLB | |
| SCHEMBL5336401 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1LMNATSHRHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049210-A1 | Heteroaryl amines as novel acetylcholinesterase inhibitors | CHEN YUHPYNG L (US) | 2002-04-25 | — | — | US | disclosed |
| US-6303633-B1 | FOR THERAPY AND PROPHYLAXIS OF ALZHEIMER'S DISEASE | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| US-6124321-A | Heteroaryl amines as novel acetyl cholinesterase inhibitors | PFIZER INC (US) | 2000-09-26 | — | — | US | disclosed |
| US-5965574-A | Heteroaryl amines as novel acetylcholinesterase inhibitors | CHEN YUHPYNG LIANG (US) | 1999-10-12 | — | — | US | disclosed |
| US-5574046-A | Heteroaryl amines as novel acetylcholinesterase inhibitors | PFIZER INC. (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0606248-A1 | HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS | Eisai Co., Ltd. (JP) | 1994-07-20 | — | — | EP | disclosed |
| WO-1993007140-A1 | HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS | PFIZER INC. (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049210-A1 | Heteroaryl amines as novel acetylcholinesterase inhibitors | ACHE, BCHE, CHAT | SMN1; SMN2 2799/4885ALDH1A1 1418/4885LMNA 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.